Invision buys majority stake in disinfectant maker Dr Deppe

Financial details were not disclosed. Equity was drawn from Invision's fifth fund, which closed on £255m in July 2013.

The GP had been eyeing the disinfectants market for some time, deeming it an attractive sector with recurring revenue from medical consumables, Invision CEO Peter Kroha told unquote".

No changes in management are planned. The fresh money will be used to grow Dr Deppe's sales internationally and expand its production site in Kempen.

Invision V follows the same investment strategy as its predecessors, investing in companies with an enterprise value between €30-100m in Germany, Austria and Switzerland.

Company
Founded in 1980 by Hans Dieter Deppe, Dr Deppe is headquartered in Kempen. The company employs 90 people and posted revenues of €20m in 2016. The business will remain under the management of the Deppe family after the transaction.

People
Invision – Peter Kroha (partner, managing director).
Dr Deppe – Titus Deppe (chief executive).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Buyouts
• DACH
• Healthcare
• Germany
• Invision Private Equity AG